Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605863 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide for Bladder Cancer Chemoprevention
A Phase 2 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02605863 is a Phase 2 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 1 participants.
The verdict
NCT02605863, a Phase 2 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).
Interventions
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605863
The ClinicalTrials.gov registry entry for NCT02605863 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enzalutamide is the first listed.
NCT02605863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02605863 about?
NCT02605863 is a clinical study titled "Enzalutamide for Bladder Cancer Chemoprevention". The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).
What is the current status of trial NCT02605863?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-01. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02605863?
The interventions under investigation include: Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02605863?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.